Background: The study aimed to evaluate the prognosis for patients with colorectal cancer who underwent surgery while receiving antithrombotic therapy (ATT) across all disease stages and for patients at disease stages 0-III.
Methods: This retrospective cohort study included 710 Japanese patients who underwent surgery for colorectal cancer between January 2009 and November 2015 at our institution. Approximately 35% of these patients received ATT. Of these, 199 (28.0%) received antiplatelet therapy, and 76 (10.7%) received anticoagulant therapy. We investigated the prognosis among patients with colorectal cancer receiving ATT, antiplatelet therapy, or anticoagulant therapy in all-stage and stage 0-III cancers.
Results: For all disease stages combined, no benefit was observed for ATT, antiplatelet therapy, and anticoagulant therapy groups in the overall survival rates (ATT: 87.8 vs. 78.4%, P = 0.23; antiplatelet therapy: 87.8 vs. 78.6%, P = 0.25; and anticoagulant therapy: 92.2 vs. 80.2%, P = 0.26). However, overall survival rates of patients with stage 0-III colorectal cancer undergoing ATT, antiplatelet therapy, and anticoagulant therapy significantly improved. (ATT: 98.5 vs. 92.7%, P = 0.01; antiplatelet therapy: 98.3 vs. 91.1%, P = 0.02; and anticoagulant therapy: 100 vs. 92.1%, P = 0.00).
Conclusion: Receiving ATT significantly improves overall survival rates in patients with stage 0-III colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571652 | PMC |
| http://dx.doi.org/10.1186/s12957-017-1235-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex Differences in the Safety and Efficacy of Different Durations of DAPT After PCI.
JACC Adv
February 2025
Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Background: Randomized controlled trials (RCTs) have examined the clinical impact of abbreviating the duration of dual antiplatelet therapy (DAPT) and have reported outcomes in men and women.
Objectives: The authors examined the safety and efficacy of different durations of DAPT following percutaneous coronary intervention (PCI) in men and women.
Methods: We searched Cochrane, Embase, MEDLINE, PubMed, Scopus, and Web of Science databases for RCTs that compared any 2 of 1, 3, 6, or 12 months of DAPT after PCI and reported outcomes in men and women.
Comprehensive review of myocardial injury after noncardiac surgery: prevention, intervention, and long-term management strategies.
J Cardiothorac Surg
January 2025
School of Medicine, American University of the Caribbean, Cupecoy, Sint Maarten.
Myocardial Injury after Noncardiac Surgery (MINS) is an increasingly recognized complication that significantly impacts postoperative morbidity and mortality. Characterized by elevated cardiac troponin levels without overt ischemic symptoms, MINS presents a challenge in perioperative care. This review article explores the epidemiology, etiology, and management of MINS, with a particular focus on prevention and the latest management strategies.
View Article and Find Full Text PDFEfficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review.
Open Heart
January 2025
The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada.
Background: Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This scoping review aimed to summarise current evidence on the safety and efficacy of anti-thrombotic therapy after MVr, identify knowledge gaps and propose a future study design.
Methods: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.
Antiplatelet Agents in Endovascular Neurointerventional Procedures.
J Neurosurg Anesthesiol
January 2025
Department of Neurology, Neurocritical Care Division, University of Pennsylvania, Philadelphia, PA.
Minimally invasive, image-guided endovascular procedures are becoming increasingly prevalent as techniques and technologies have advanced, particularly within the realm of neurovascular interventions. Endovascular approaches ubiquitously result in endothelial injury with subsequent risk of thromboembolic complications. Periprocedural antiplatelet agent use is an integral component of the management of patients undergoing endovascular neurointerventional procedures.
View Article and Find Full Text PDFImpacts on Postoperative Bleeding of Surgery for Head and Neck Malignancies While Continuing Antithrombotic Agents.
Int Arch Otorhinolaryngol
January 2025
Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Perioperative management of antithrombotic agents may affect bleeding and lead to thromboembolic complications, but there is no consensus on optimal protocol in head and neck surgery. To explore the effect of antithrombotic agents on postoperative bleeding. We compared clinical characteristics, type of surgery, antithrombotic agents, continued use of medication or not, and frequency of postoperative bleeding among patients who were receiving antithrombotic therapy at the time of their decision to undergo surgery for head and neck malignancies, from 2008 to 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!